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Abstract 
Background: Single nucleotide variants (SNVs) are detected as different 
distributions of DNA samples of distinct types of cancer patients. Even though, it is 
an exacting task to select the appropriate method to identify cancer to the greatest 
extent of SNVs. 
Results: In this paper, we proposed a biomarker concept based on SNV patterns in 
different feature dimensions. Raw dataset (2761 samples) consisting of twelve 
different cancers was obtained from TCGA (The Cancer Genome Atlas). After 
preliminary screening of 562,321 DNA mutation sites in the samples, the mutation 
sites were extracted and characterized by cancer types in six different SNV feature 
dimensions. In this study, we found that the extracted features showed similar 
distribution in the cluster center of the disease type of the samples. After the initial 
processing of the raw data, the sample was more focused on the subtype distribution 
of the cancer or the cancer at the SNV level. We used k-nearest neighbors (KNN) to 
classify the extracted features and Leave-One-Out cross verified them. The accuracy 
of classifying is stable at around 97% and reached 97.43% at the highest. During the 
validation phase, we found validated oncogenes in the loci of the features with the 
highest importance among nine cancers. 
Conclusions: In summary, the samples showed consistent patterns according to the 
cancer in which it belongs. It is feasible to classify the cancer of the sample by the 
distribution of different dimensions of the SNVs and has a high accuracy. And has 
potential implications for the discovery of cancer-causing genes. 
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Introduction 
Cancer is expected to rank as the leading cause of death and the single most 
important barrier to increasing life expectancy in every country of the world in the 
21st century.[1] Large-scale tumour-sequencing studies have demonstrated that the 
majority of cancers are driven by either SNVs or SVs. There is currently a bias 
towards clinical sequencing of SNVs rather than SVs. [2]How to use SNVs to detect 
cancers as biomarkers efficiently and accurately is crucial. In earlier studies, using 
genetic mutations for cancer classification, the Cancer Genome Atlas Research 
Network performed mutational signature analysis on the core set of 196 
hepatocellular carcinoma (HCC) applying a Bayesian variant of the non-negative 
matrix factorization (NMF) algorithm to mutation counts of SNVs stratified by 96-
trinucleotide contexts.[3] In order to obtain the characteristics of the cancer, 
decompose the matrix used to carry the DNA mutation sites of the cancer by 
assuming that the DNA mutations is subjected to a specific distribution. Another 
earlier study developed a panel of DNA methylation biomarkers and validated their 
diagnostic efficiency for non-small cell lung cancer (NSCLC) in a large Chinese Han 
NSCLC retrospective cohort. The accuracy was 91% in their Bayes tree model.[4] 
These are the current two representative genetic mutation-based studies on cancer 
classification. The former research did not use specific genes as a basis, but uses 
trinucleotide to count the mutations of patients and identify the characteristics. The 
latter selected specific genes and used mutations in these genes to detect cancers. Due 
to the limitations of the data itself, the number of samples for these two studies is 
generally less than two hundred. 
 Figure 1 The design framework of the study Raw dataset contains 562K mutation sites which 
belong to 2761 samples. We screened all samples, and the retained samples must belong to SNV 
in somatic cells. And extracted different feature matrices as processed data with different feature 
dimensions. For the twelve cancers in the dataset, each cancer produced six M * N matrices, 
where M represents the number of samples contained in the cancer, and N represents the number 
of mutation types in the current feature pattern. Two operations were performed on the matrix: 1. 
The cancer subtypes are obtained by clustering the samples in the matrix. The samples in the 
matrix were manually labeled with subtypes and classified using Euclidean distance to verify the 
concept of SNV subtype distribution. 2. KNN classification was performed on the samples to 
verify the existence of specific distribution patterns separated by cancer in SNVs. 
In this paper, to investigate the potential relationship between cancers and SNV 
patterns (Figure 1), We counted the SNVs of all patients with all twelve cancers, and 
extracted the features for each cancer according to six different feature dimensional 
extraction methods, then set up six mutation counting matrices to store six different 
patterns of mutation features. It was equivalent to expanding the dataset by six times. 
We classified all twelve cancers’ samples and tested it using leave-one-out cross 
validation. The accuracy of cancer classification (KNN) by statistical SNV 
distribution patterns was 97.43%. 
Result 
Raw dataset collection, feature extraction and matrix construction 
We downloaded the eligible Mutation Annotation Format (MAF) files from 
TCGA as much as possible, which contained a large number of information about the 
mutation sites of twelve cancers, including their reference alleles and six to ten 
adjacent bases (both left and right), and mutant alleles at these sites. Twelve types of 
cancer include: Liver hepatocellular carcinoma (LIHC), Kidney renal papillary cell 
carcinoma (KIRP), Lung adenocarcinoma (LUAD), Prostate adenocarcinoma 
(PRAD), Lung squamous cell carcinoma (LUSC), Uterine Corpus Endometrial 
Carcinoma (UCEC), Thyroid carcinoma (THCA), Rectum adenocarcinoma (READ), 
Head and Neck squamous cell carcinoma (HNSC), Bladder Urothelial Carcinoma 
(BLCA), Acute Myeloid Leukemia (LAML), Pancreatic adenocarcinoma (PAAD). 
The data obtained from TCGA cannot be used directly. Take LUSC as an 
example, it's MAF file contains 48,746 mutation sites belonging to 178 patients. The 
distribution of variants is shown in Figure 2. Cancer is a complex disease often 
associated with a characteristic series of somatic genetic variants.[5] Therefore, we 
only used somatic mutation sites where the mutation type is SNP (base substitution). 
After screening, 47,916 mutation sites were left. 
 
Figure 2 Distribution of variants in LUSC.  A Distribution of SNV classes, the total number of 
mutation sites is 48,746, respectively belonging to SNP (substitution), INS (insertion), DEL 
(deletion). B Distribution of six basic base substitutions 
 The screening of mutation sites is the premise of feature extraction. After this 
step, we need to extract the features of interest from the original data, which are 
SNVs. We proposed the concept of the SNV feature dimensions to improve data 
utilization. The general classification of single nucleotide variations is based on the 
six kinds of base substitutions of nucleotides. For any SNV, the base (A, T, C, G) can 
be replaced by the remaining three, which result in 12 substitutions. Due to the 
complementary relationship of bases, the substitution is reduced to six (C>A, C>G, 
C>T, T>A, T>C, T >G). In order to facilitate the distinction, we refer to such a one-
dimensional feature by replacing one nucleotide of the mutation site itself. 
 The probability of a somatic single-nucleotide variant (SNV) to occur can depend 
on the sequence neighborhood[6]. Therefore, we combined the mutation site with its 
neighboring bases to form multi-dimensional features. For example, for a mutation 
site C>A, assuming that it’s left nucleotides are T.C and the right nucleotides are G.A, 
obviously when taking a one-dimensional feature, only the mutation site itself is 
taken. The feature is C>A itself. When the feature dimension is extended to two-
dimensional, two different features can be obtained due to different selection of the 
direction of feature expansion (when expanding to the left: C.C>A, when expanding 
to the right: C>A.G). The two-dimensional features may add a single base to the left 
or right to make the possible mutation type 2*24. Similarly, when the feature 
dimension is extended to three-dimensional, we can again acquire three new sets of 
features (when expanding to the left: T.C.C>A, when expanding to both sides: 
C.C>A.G , when expanding to the right: C>A.G.A). Among these three sets of 
features, each set of features has 96 types that may appear. Considering that the 
distribution of data has been sparse when expanding to three-dimensional, we only 
extended the features to three-dimensional, which gave us six sets of features. 
 After the feature extraction patterns is established, the sample features can be 
statistically calculated. We converted the sample features into six groups of M*N 
matrices in six different patterns (M is the number of samples, and N is the number of 
mutation types in the current pattern). For example, with regard to 178 patients with 
LUSC, using one-dimensional as the feature extraction pattern, a 178*6 matrix W1 
can be established. W1’s any element 𝑊𝑖𝑗 represents number of No. j mutation in the 
No. i sample. By traversing the 47,916 mutation sites in turn, we can obtain a 
complete one-dimensional feature matrix. The sum of all elements of the matrix is 
equal to the total number of mutation sites. After the feature collection of the data in 
the order of the six feature patterns, the different patterns are equivalent to observing 
the data at different angles, which is equivalent to expanding the data by six times. 
Once these matrices are obtained, the processing of the data is complete, then we can 
analyze the association of the data with cancers. 
Association of SNV biomarkers with cancer subtypes 
In our earlier work, we selected PRAD, LIHC, and LUAD as the initial dataset, 
and converted the distribution of all SNVs in the same cancer into six groups of 
matrices representing the distribution of various types of mutation sites. In order to 
confirm the existence of a special SNV overall distribution for each cancer, we added 
the performance of each row in the matrix by the mutation type of each pattern and 
divided by the total number of samples to obtain a uniform distribution of the 
samples. When we tried to classify the test set by using the obtained uniform 
distribution as the standard, we found that the effect was not stable. The performance 
of PRAD was satisfied with expectations, the classification accuracy was about 98%, 
but LIHC and LUAD could only reach 70%~80%. 
 The prevalence of somatic mutations was highly variable between and within 
cancer classes.[7] We have observed all the samples individually to find out the 
problem. To control experiment cycle and cost, we selected five cancers from the raw 
data set to form a sub-dataset, including Lung Adenocarcinoma (LUAD), Lung 
squamous cell carcinoma (LUSC), Prostate adenocarcinoma (PRAD), Kidney renal 
papillary cell carcinoma (KIRP), Liver hepatocellular carcinoma (LIHC). In this way, 
the diseased areas of cancer were differentiated as a whole, yet the association 
between different cancers in the same diseased area (LUAD and LUSC) was also 
considered. Study showed that even with the same cancer, the internal SNV 
distribution does not necessarily obey only one single overall distribution. However, 
the occurrence of SNV is not completely random. In the five cancers of the dataset, 
SNVs are often subjected to one to three major distributions. The main distributions 
of the five cancers is shown in Figure 3. 
 
Figure 3 One-dimensional feature distribution of cancers Since high-dimensional features are 
extensions of low-dimensional features, one-dimensional features were used here as representative 
of the distribution of SNVs in cancers. Each line chart illustrates the distributions of major 
subtypes in the belonging cancer. The abscissa represents the six types of mutation site 
substitutions in the one-dimensional pattern, and the ordinate represents the average number of 
each substitution type of all samples that belong to the subtype in the current cancer. 
It is worth noticing that the labeled subtypes do not fully cover all the samples. 
This is because the subtype labels were manually labeled by the researcher. Before we 
labeled the subtype labels, we first calculated the mean distribution of all the samples' 
one-dimensional features, and this distribution was referred to as the first subtype. 
The samples that apparently did not conform to the first subtype were then manually 
selected as new subtypes. The number of samples selected for the new subtype must 
be greater than 10%, which means, it is not accidental, but there is indeed a portion of 
the samples around this distribution. We selected three subtypes for each type of 
cancer at most to avoid overfitting, and samples that did not conform to the selected 
subtypes remained in the first subtype cluster. 
To verify that these subtypes do exist, we randomly used 80% of the dataset as 
the training set and 20% of the dataset as the test set. In order to clearly obtain the 
classification results, we selectively filtered some samples that should satisfy: very 
inconsistent with any established subtypes, the mutations that occur are too few or too 
large to be analyzed, too close to other cancer subtypes will inevitably be classified 
incorrectly, and all three types must satisfy the condition that the number of 
occurrences is rarely enough to constitute a new subtype. The above sample filtering 
was only for the purpose of observing the classification results of subtypes, and has 
been removed in practical applications. Since the distribution of SNVs in the samples 
is expressed in digital form, we used different formulas to calculate the distances 
between the test set and the 13 subtypes in the training set in the six feature patterns, 
and linearly accumulate these distances. The Euclidean distance with the best 
classification result is selected as the calculation standard, we took the nearest subtype 
as the classification result. Compare to defaulting the SNVs of a cancer to consistent 
distribution, the classification results of subtypes have improved significantly and 
stably, from 80% to 91%. The distance calculation formula is as follows: 
𝐷𝑖𝑠𝑡(𝑋, 𝑌) = ∑ √∑(𝑥𝑖𝑗 − 𝑦𝑖𝑗)2
𝑛𝑖
𝑗=1
6
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X and Y represent any two samples in the sample set, i represents six feature 
extraction patterns, 𝑛𝑖 represents the number of base substitution types in different 
feature patterns, j represents each type of base substitution, 𝑥𝑖𝑗 and  𝑦𝑖𝑗 represent 
the number of No. j substitution in the No. i pattern. 
It should be noted that we found that the distance between the sample with the 
wrong classification and the subtype of the cancer that the sample actually belongs to 
is often very close to the distance of the misclassified cancer and the sample, which 
means that even the sample with the wrong classification is not uncontributed. We 
chose the subtype with the smallest distance as the classification result to obtain the 
classification result intuitively, but in practical application, we should consider the 
case where the distance is close, so that even the misclassified samples could narrow 
the classification result to very small range. 
Classification of cancer based on SNV biomarkers and validation 
In later studies, to actually apply the SNV multi-feature patterns to cancer 
classification, we used a better algorithm to classify the samples instead of simply 
performing distance estimation. K-Nearest Neighbor (KNN) is considered a very 
common algorithm when using distance to measure samples[8], and KNN is also very 
suitable for the data type of the samples. We used Euclidean distance that performed 
well in previous studies to calculate the distance between test samples and other 
labeled samples. The experimental results of KNN are shown in Table 1 and Figure 4.  
Table 1 Sample numbers and classification results of twelve cancers We found that the 
accuracy of LAML is lower than other cancers. This is because there are several samples with too 
sparse mutations in LAML, which cannot make the samples well classified. 
Cancer Type Sample Number 2-NN Accuracy 
LIHC 198 0.9697 
KIRP 282 0.9716 
LUAD 230 0.9870 
PRAD 259 0.9575 
LUSC 178 0.9775 
UCEC 194 0.9897 
THCA 425 0.9765 
READ 161 0.9938 
HNSC 364 0.9780 
BLCA 130 0.9846 
LAML 151 0.9338 
PAAD 189 0.9683 
ALL 2761 0.9743 
In order to verify our proposed marker concept, we ranked the genes included in 
the top features by the number of mutations by ranking the importance of 342 features 
in nine cancers. Discovered oncogenic genes have been found in every type of cancer, 
including NARS and HARS in THCA; KRAS in LUAD, etc. This not only proves 
the effectiveness of SNV as a marker, but also provides research ideas for potential 
oncogenes. 
 Figure 4 The effect of K value on accuracy We performed a classification effect test on different 
values of K. Performed Leave-One-Out cross validation for each K value in the 12 cancer 
classifications. The accuracy reached the highest (97.43%) when k was 1 or 2. 
 
Conclusions and future work 
In this paper, we found that although SNVs are altered in cancer, they still follow 
one or several overall distributions. In the experiment, we demonstrated the positive 
effects of multi-dimensional features of SNV biomarkers on cancer classification, 
extending only to three-dimensional, the classification accuracy is improved by 10% 
to 20%. Efficient cancer classification was achieved by using the KNN algorithm, and 
the accuracy reached 97.43% at the highest.  
In fact, because our proposed classification of cancer based on SNV patterns is a 
brand-new method, after investigation of other studies, we found that the study of 
multi-class cancer classification is generally to analyze images (x-rays) or genes. The 
data we used did not find that pre-study studies were used in multi-class cancer 
classification, since the datasets were different, there was no gold standard set, which 
made it difficult to compare the experiments. However, we found that the accuracy of 
existing research on multi-class cancer classification is generally 85% to 95% [9-12], 
which indirectly proves that our model is valuable. 
Limited to the source of experimental data, we haven’t verified the association 
between SNV subtypes and cancer subtypes. In the future work, we can further refine 
the subtypes of cancer and explore the relationship between SNV patterns and 
cancers. In addition, multi-class cancer classification using the multi-dimensional 
SNV patterns is also feasible and has high precision. 
Core code and example dataset 
Our core code and example dataset have been written as a R package and can be 
found at: 
https://github.com/Lee0510/SNVCC 
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